TY - JOUR
T1 - Phospholipase A2 activities in skin physiology and pathology
AU - Dan, Phyllis
AU - Rosenblat, Gennady
AU - Yedgar, Saul
PY - 2012/9/15
Y1 - 2012/9/15
N2 - Skin inflammatory diseases are most commonly treated with corticosteroids, especially topical preparations, benefitting from high potency and unparalleled formulation flexibility. However, these benefits are limited due to side effects, especially under long-term use. Non-steroidal anti-inflammatory drugs (NSAIDs) which block the COX pathways have been used as safer alternatives to corticosteroids, and much effort and resources have been invested in developing COX inhibitors. However, synthetic NSAIDs are less potent than steroids, have limited formulation flexibility and have their own safety issues, thereby yielding unsatisfactory results, with some high-profile drugs (e.g., the COX-2 inhibitors Vioxx®, Celebrex®) being withdrawn from the market due to safety concerns. The potency and safety challenges of NSAIDs are related to inter-eicosanoid dynamics, pertaining to their pro-versus anti-inflammatory action, homeostatic functions and tissue-specific activities. Instead, the upstream control of phospholipase A2 (PLA2) enzymatic activity, which hydrolyzes cell membrane phospholipids to initiate the eicosanoid production, has been considered for inhibiting eicosanoid activation while maintaining the intricate balance needed for their homeostatic functions. Yet, PLA2 inhibitors have hardly been tested for treating skin inflammatory/allergic conditions. In this article we review the involvement of PLA2s in skin physiology and pathology, and discuss the prospect of PLA2 inhibition for the treatment of dermatological diseases.
AB - Skin inflammatory diseases are most commonly treated with corticosteroids, especially topical preparations, benefitting from high potency and unparalleled formulation flexibility. However, these benefits are limited due to side effects, especially under long-term use. Non-steroidal anti-inflammatory drugs (NSAIDs) which block the COX pathways have been used as safer alternatives to corticosteroids, and much effort and resources have been invested in developing COX inhibitors. However, synthetic NSAIDs are less potent than steroids, have limited formulation flexibility and have their own safety issues, thereby yielding unsatisfactory results, with some high-profile drugs (e.g., the COX-2 inhibitors Vioxx®, Celebrex®) being withdrawn from the market due to safety concerns. The potency and safety challenges of NSAIDs are related to inter-eicosanoid dynamics, pertaining to their pro-versus anti-inflammatory action, homeostatic functions and tissue-specific activities. Instead, the upstream control of phospholipase A2 (PLA2) enzymatic activity, which hydrolyzes cell membrane phospholipids to initiate the eicosanoid production, has been considered for inhibiting eicosanoid activation while maintaining the intricate balance needed for their homeostatic functions. Yet, PLA2 inhibitors have hardly been tested for treating skin inflammatory/allergic conditions. In this article we review the involvement of PLA2s in skin physiology and pathology, and discuss the prospect of PLA2 inhibition for the treatment of dermatological diseases.
KW - COX (cyclooxygenase)
KW - Free fatty acid
KW - Phospholipase A
KW - Phospholipase A inhibitor
KW - Phospholipid
KW - Skin disease
UR - http://www.scopus.com/inward/record.url?scp=84865037143&partnerID=8YFLogxK
U2 - 10.1016/j.ejphar.2012.07.023
DO - 10.1016/j.ejphar.2012.07.023
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.systematicreview???
C2 - 22819703
AN - SCOPUS:84865037143
SN - 0014-2999
VL - 691
SP - 1
EP - 8
JO - European Journal of Pharmacology
JF - European Journal of Pharmacology
IS - 1-3
ER -